tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Haemonetics price target lowered to $85 from $105 at BTIG

BTIG lowered the firm’s price target on Haemonetics (HAE) to $85 from $105 and keeps a Buy rating on the shares. The company’s Q1 beat was driven by the Plasma segment and helped by Blood Management Tech and Blood Center Sales, the analyst tells investors in a research note. The firm added that it remains constructive on Haemonetics but needs to see improvement in the Vascade franchise throughout this fiscal year, and reduced its price/equity multiple to 15x from 18.5x, roughly in line with the media of the comp group, to arrive at its new price target

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1